First patient gets Biogen's newly approved Alzheimer's drug
Updated: 2021-06-17 07:04:56 KST
A controversial drug is giving hope for those facing Alzheimer's as well as for their loved ones.
Biogen's newly approved Alzheimer's drug Aduhelm was given to a patient for the first time on Wednesday.
The recipient, a 70-year-old man from Rhode Island.
"Well, it's emotional and to think that I don't have to think about the last stage."
But the average price of the drug is 56-thousand U.S. dollars per year, which the Alzheimer's Association,which has been a longtime supporter of Biogen, claims is "simply unacceptable".
Aduhelm is the first medication cleared by U.S. Food and Drug Administration that slows cognitive decline in people with Alzheimer's.
Despite disapproval from many experts due to a lack of clinical data, some believe it's a turning point in treatment of the disease.